Alluvi, known as BI 4744, presents a promising breakthrough in weight management treatment. This dual stimulator targeting both GLP-1 and GIP targets demonstrates remarkable results in clinical trials, possibly https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/